Abstract:Background: Although several studies have determined quality of life in patients with lung cancer, there is still little information about the use of generic questionnaires [e.g. the 36-item Short Form health survey (SF-36)] and utility questionnaires [e.g. the EuroQOL instrument (EQ-5D)] in this disease.Objectives: To (i) measure quality of life and utility in patients with non-small cell lung cancer (NSCLC) using the SF-36 and the EuroQOL questionnaires; (ii) to evaluate the impact of some clinical variables on quality of life and utility; (iii) to assess the correlation between the measurements produced by the 2 questionnaires.Study design: Cross-sectional study.Participants: 95 patients from15 Italian hospitals with NSCLC (93% male, mean age 62 years) completed both questionnaires.Results: The mean scores for the 8 domains of the SF-36 ranged from 20.8 (physical role) to 63.0 (social functioning). The mean physical and mental summed scores of the SF-36 were 36.8 [standard deviation (SD) 9.8] and 43.0 (SD 11.5), respectively. The EuroQOL mean score was 0.58 (SD 0.32) in the self-classifier (SC) version and 0.58 (SD 0.20) in the visual analogue scale (VAS) version. Among the clinical variables that affected quality of life and utility, the presence of metastasis had the greatest impact: patients with metastasis had statistically significantly lower scores for 2 domains of the SF-36 (physical functioning, p = 0.009; bodily pain, p = 0.016), for the physical component summed score of the SF-36 (p = 0.015) and for both utility estimates (EuroQOL-SC, p = 0.027; EuroQOL-VAS, p = 0.038) than patients without metastasis. Both the SC and VAS EuroQOL scores showed a statistically significant correlation with each of the 8 domains of the SF-36. The scores for both the SF-36 and the EuroQOL in patients with NSCLC were considerably worse (relative differences ranging from −8 to −73%) than the corresponding values (normative data) previously reported for healthy individuals.Conclusions: Our study quantified the degree to which quality of life is impaired in patients with NSCLC, showed that the presence of metastasis had an important role, and indicated a strong correlation between the measurements produced by the 2 questionnaires. The EuroQOL measurements obtained from these patients will aid evaluation of the cost-utility ratio for NSCLC therapies.

Health-related quality of life after first-line anti-cancer treatments for advanced non-small cell lung cancer in clinical practice

P3.02a-014 Patient Reported General Health Status in a Study of Crizotinib Versus Chemotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC)

Quality of Life in Patients with Advanced Non-Small-Cell Lung Cancer: A Prospective real-world study

Crizotinib in Patients with Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Versus Chemotherapy As a First-Line Treatment

Monitoring changes in quality of life in patients with lung cancer by using specialised questionnaires: implications for clinical practice

Prognostic effects of health-related quality of life at baseline and early change in health-related quality of life on response to treatment and survival in patients with advanced lung cancer: a prospective observational study in China

Clinical Benefit of Gemcitabine Plus Cisplatin 3-Week Regimen for Patients with Advanced Non-Small Cell Lung Cancer: a Prospective Observational Study.

[A Randomized, Controlled, Multicenter Clinical Trial Comparing Pemetrexed/cisplatin and Gemcitabine/cisplatin As First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer].

Outcome of Advanced Nonsmall Cell Lung Cancer Patients Receiving Gemcitabine and Weekly Paclitaxel As First-Line Treatment

Shenlingcao Oral Liquid for Patients with Non-Small Cell Lung Cancer Receiving Adjuvant Chemotherapy after Radical Resection: A Multicenter Randomized Controlled Trial

Quantitative comparison of the efficacies and safety profiles of three first-line non-platinum chemotherapy regimens for advanced non-small cell lung cancer

Efficacy of Pemetrexed Plus Platinum Doublet Chemotherapy As First-Line Treatment for Advanced Nonsquamous Non-Small-cell-lung Cancer: a Systematic Review and Meta-Analysis.

Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review

The impact of chemotherapy on quality of life in advanced-stage lung cancer patients

Influences of China-Made Gemcitabine Plus Platinum Regimen on the Quality of Life among Patients with Advanced Non-Small Cell Lung Cancer

Updated Efficacy and Quality-of-life (qol) Analyses in OPTIMAL, a Phase III, Randomized, Open-Label Study of First-Line Erlotinib Versus Gemcitabine/carboplatin in Patients with EGFR-activating Mutation-Positive (EGFR Act Mut+) Advanced Non-Small Cell Lung Cancer (NSCLC).

Quality of Life and Utility in Patients with Non-Small Cell Lung Cancer

Clinical Evaluation of Serum Tumor Markers in Patients with Advanced-Stage Non-Small Cell Lung Cancer Treated with Palliative Chemotherapy in China

Quality of Life in Lung Cancer Patients Undergoing Concurrent Chemoradiotherapy

The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study

Chinese Herbal Medicine As Maintenance Therapy for Improving the Quality of Life for Advanced Non-Small Cell Lung Cancer Patients